306 related articles for article (PubMed ID: 15550585)
1. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.
Rueda Domínguez A; Márquez A; Gumá J; Llanos M; Herrero J; de Las Nieves MA; Miramón J; Alba E
Ann Oncol; 2004 Dec; 15(12):1798-804. PubMed ID: 15550585
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
4. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study.
Rueda A; Alba E; Ribelles N; Sevilla I; Ruiz I; Miramón J
J Clin Oncol; 1997 Mar; 15(3):1118-22. PubMed ID: 9060553
[TBL] [Abstract][Full Text] [Related]
5. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
6. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
7. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
8. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
9. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
[TBL] [Abstract][Full Text] [Related]
10. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
12. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
13. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
[TBL] [Abstract][Full Text] [Related]
15. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
16. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
[TBL] [Abstract][Full Text] [Related]
17. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
18. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy.
van den Berg H; Stuve W; Behrendt H
Med Pediatr Oncol; 1997 Jul; 29(1):23-7. PubMed ID: 9142201
[TBL] [Abstract][Full Text] [Related]
20. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.
Björkholm M; Axdorph U; Grimfors G; Merk K; Johansson B; Landgren O; Svedmyr E; Mellstedt H; Holm G
Ann Oncol; 1995 Nov; 6(9):895-9. PubMed ID: 8624292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]